What is the best treatment for constipation in an adult with type 2 diabetes taking Ozempic (semaglutide), such as linaclotide?

Treatment for Ozempic-Induced Constipation

Start with polyethylene glycol (PEG) as first-line therapy, and if constipation persists despite standard laxatives, linaclotide (Linzess) is an appropriate and effective second-line option for managing Ozempic-related constipation.

Understanding the Problem

Constipation is a recognized gastrointestinal side effect of semaglutide (Ozempic), occurring due to delayed gastric emptying and slowed intestinal transit—the very mechanisms that contribute to its glucose-lowering and weight-loss effects 1. While the FDA label acknowledges gastrointestinal adverse reactions including constipation, it doesn't provide specific management guidance 1.

Stepwise Treatment Approach

First-Line: Osmotic Laxatives

Begin with polyethylene glycol (PEG) as your initial pharmacological intervention 2. The 2023 AGA-ACG guidelines on chronic idiopathic constipation provide a strong recommendation for PEG, supported by high-quality evidence 2. PEG works by sequestering fluid in the bowel through osmotic action, is well-tolerated, and can be titrated to achieve one non-forced bowel movement every 1-2 days 3.

• Dosing: Standard PEG formulations can be adjusted based on response
• Advantages: Minimal systemic absorption, predictable effect, generally well-tolerated
• Alternative osmotic agents: Lactulose or magnesium-based products if PEG is not tolerated 3

Adding Stimulant Laxatives

If osmotic laxatives alone are insufficient, add bisacodyl (10-15 mg, 2-3 times daily) or senna 4. These stimulant laxatives increase intestinal motility by stimulating the myenteric plexus and can be used in combination with osmotic agents 3.

Second-Line: Linaclotide (Linzess)

When standard laxative therapy fails, linaclotide is an evidence-based option 5, 2. While the guidelines specifically address IBS-C and chronic idiopathic constipation rather than drug-induced constipation, the mechanism is relevant:

• Mechanism: Linaclotide is a guanylate cyclase-C agonist that stimulates intestinal fluid secretion and accelerates transit 4, 6
• Evidence quality: Strong recommendation with high-quality evidence for constipation management 5
• Efficacy: Significantly improves spontaneous bowel movements, stool consistency, straining, and abdominal symptoms 6, 7, 8
• Dosing: 145 mcg or 290 mcg once daily (the 145 mcg dose for chronic constipation, 290 mcg for IBS-C) 9, 6

Key consideration: Diarrhea is the most common side effect, occurring in 6-17% of patients depending on dose 7. This is actually dose-related and generally manageable—only about 5-9% of patients discontinue due to adverse events 7.

Alternative Secretagogues

If linaclotide is not available or not tolerated:

• Lubiprostone: A chloride channel activator with strong evidence (moderate quality) 5. Less likely to cause diarrhea than linaclotide but nausea is more common 5
• Plecanatide: Another guanylate cyclase-C agonist with similar efficacy to linaclotide 5, 9

Important Clinical Caveats

Rule Out Mechanical Obstruction

Before escalating therapy, always assess for bowel obstruction, particularly given emerging case reports of GLP-1 agonists causing ileus or small bowel obstruction 10, 11. Check for:

• Severe abdominal pain
• Vomiting
• Abdominal distension
• Absence of bowel sounds

If obstruction is suspected, do not use secretagogues or aggressive laxatives—these are contraindicated 4, 12, 4.

Monitor for Dehydration and Renal Function

The FDA label warns about dehydration risk from GI adverse reactions with Ozempic 1. When treating constipation aggressively:

• Ensure adequate fluid intake
• Monitor for signs of volume depletion
• Be particularly vigilant in patients with pre-existing kidney disease, as acute kidney injury has been reported with severe GLP-1-related GI complications 10

Consider Dose Adjustment of Ozempic

If constipation is severe and refractory, discuss with the prescribing provider whether:

• Temporarily reducing the Ozempic dose is appropriate
• The patient has been recently up-titrated (as this increases GI side effects) 10, 13
• The benefits of continuing Ozempic outweigh the constipation burden

What NOT to Do

Avoid peripherally-acting mu-opioid receptor antagonists (methylnaltrexone, naloxegol, naldemedine) as these are specifically for opioid-induced constipation and won't address GLP-1-mediated mechanisms 4, 12, 4.

Don't use prokinetic agents like metoclopramide routinely—while they may theoretically help, the evidence is limited, and metoclopramide carries risks of tardive dyskinesia with long-term use 3.

Bottom Line Algorithm

1. Start: PEG (osmotic laxative) with adequate hydration
2. If inadequate: Add bisacodyl or senna (stimulant laxative)
3. If still refractory: Linaclotide 145 mcg daily (or lubiprostone as alternative)
4. Throughout: Rule out obstruction, ensure hydration, consider Ozempic dose adjustment if severe

This approach is grounded in the strongest available guideline evidence for constipation management 2, adapted to the specific context of GLP-1 agonist therapy.